Use of lentiviral vectors in vaccination.

Antigen expression in vivo humoral immunity lentiviral vectors long-lasting immune memory non-integrating lentiviral vectors t-cell immunity transduction vaccination

Journal

Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 9 10 2021
medline: 24 12 2021
entrez: 8 10 2021
Statut: ppublish

Résumé

Lentiviral vectors have emerged as powerful vectors for vaccination, due to their high efficiency to transduce dendritic cells and to induce long-lasting humoral immunity, CD8 Here, we reviewed the literature, highlighting the relevance of lentiviral vectors in vaccinology. We recapitulated both their virological and immunological aspects of lentiviral vectors. We compared lentiviral vectors to the gold standard viral vaccine vectors, i.e. adenoviral vectors, and updated the latest results in lentiviral vector-based vaccination in preclinical models. Lentiviral vectors are non-replicative, negligibly inflammatory, and not targets of preexisting immunity in human populations. These are major characteristics to consider in vaccine development. The potential of lentiviral vectors to transduce non-dividing cells, including dendritic cells, is determinant in their strong immunogenicity. Notably, lentiviral vectors can be engineered to target antigen expression to specific host cells. The very weak inflammatory properties of these vectors allow their use in mucosal vaccination, with particular interest in infectious diseases that affect the lungs or brain, including COVID-19. Recent results in various preclinical models have reinforced the interest of these vectors in prophylaxis against infectious diseases and in onco-immunotherapy.

Identifiants

pubmed: 34620025
doi: 10.1080/14760584.2021.1988854
doi:

Substances chimiques

Viral Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1571-1586

Auteurs

Min-Wen Ku (MW)

Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France.

Pierre Charneau (P)

Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France.

Laleh Majlessi (L)

Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH